摘要
HER-2/neu基因,又名c-erbB2,定位于人染色体17q21,编码185kD的跨膜糖蛋白(p185),p185在乳腺、卵巢、肺、胃、前列腺等十余种癌症中均显示部分患者有过量表达,p185蛋白作为一个重要的肿瘤表面标记蛋白,尤其对乳腺癌,已被国际公认是重要的临床指标。目前国外已有上市的免疫组化Herceptest试剂盒和Herceptin药物用于检测和靶向治疗乳腺癌,但乳腺癌的测定方法的标准化及新的检测方法还须进一步研究。
HER-2/neu gene,also named c-erbB2, locates at human chromosome 17q21, encodes the transmembrane glycoprotein of 185kD(p185). Some researches demonstrated that p185 was overdose express in decades of cancers such as breast cancer, ovarian cancer, lung cancer, stomach cancer, prostate cancer exist in some patients. As a significant marking protein of tumor surface, the protein p185 becamed a significant clinical index of international generally accepted. At present, there are the kit immunohistochemistry Herceptest and the drug Herceptin on sale abroad. They are used in detecting and targeting therapy the breast cancer separately, but the assay method standardization of breast cancer and new detection method request more study and research.
出处
《生物学杂志》
CAS
CSCD
2008年第1期5-8,共4页
Journal of Biology
基金
国家863项目(2004AA215860)
关键词
原癌基因
肿瘤表面标记蛋白
单克隆抗体
proto-oneogene
tumor sufaee marking protein
monoelonal antibody